A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Objective
To determine if nivolumab + chemo-immunotherapy results in a superior long term PFS (events defined as disease progression confirmed by central review or death) when compared with chemo- immunotherapy alone in patients with newly diagnosed primary mediastinal B-cell lymphoma.
